← Eichor
Condition: Tocilizumab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tocilizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptom
Phase 2 · 1 location(s) · Lorenzo delSorbo · NCT07334379A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administrati
Phase 2 · 1 location(s) · Janssen Research & Development, LLC · NCT07589634TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Phase 3 · 8 location(s) · Vastra Gotaland Region · NCT04561986A Pilot Study in Severe Patients With Takayasu Arteritis.
Phase 4 · 1 location(s) · Shanghai Zhongshan Hospital · NCT04300686Tocilizumab in Lung Transplantation
Phase 2 · 21 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06033196Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
NA · 1 location(s) · Shahid Beheshti University of Medical Sciences · NCT07006532Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?
NA · 1 location(s) · University Hospital, Clermont-Ferrand · NCT06654154TocILizumab in aorTitis in GCA (TILT)
Phase N/A · 1 location(s) · Groupe français d'étude des Maladies Inflammatoires de loeil · NCT06271018Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st
Phase 1/Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT04691817Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Phase 2 · 7 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07108387Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Even
Phase 3 · 47 location(s) · AbbVie · NCT05609630Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
Phase 4 · 1 location(s) · Radboud University Medical Center · NCT06624436Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
NA · 1 location(s) · Marmara University · NCT07491913Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
Phase 1 · 1 location(s) · University of Florida · NCT06863480A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa
Phase 4 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06927375Neutralizing Interleukin (IL)-6
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT07493317Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Phase 3 · 1 location(s) · National Institute of Geriatrics, Rheumatology and Rehabilit · NCT06297096SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Phase 2 · 6 location(s) · Kathy Miller · NCT05846789Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06818266Tocilizumab for Acute Chest Syndrome
Phase 2 · 1 location(s) · University of Chicago · NCT05640271Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT06016179RCT of Tocilizumab for Anti-MDA5+DM
NA · 1 location(s) · Peking Union Medical College Hospital · NCT07377058PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Phase 2 · 1 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06430736Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Phase 3 · 408 location(s) · UMC Utrecht · NCT02735707Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT05845723ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2 · 14 location(s) · Nationwide Children's Hospital · NCT05233397Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Phase 2 · 6 location(s) · Tang-Du Hospital · NCT05067348
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.